Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or ...

SunRISe-4 evaluates TAR-200 and cetrelimab in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy, showing promising pathological response rates. Adverse events were ...

Please review different treatment delivery options available for management of NMIBC. It is an exciting time for NMIBC, as several delivery systems and agents are currently under investigation for ...

Trinity Bivalacqua presented updated results from the BOND-003 cohort C study at EAU 2025, evaluating the efficacy and safety of intravesical cretostimogene grenadenorepvec in high-risk ...

EAU 2025: Discussant: NIAGARA - Surgical Outcomes and Neoadjuvant Safety with Perioperative Durvalumab for Muscle-Invasive Bladder Cancer EAU 2025: Rapid-Fire Debate: Patient with High-Risk NMIBC - Is ...

Browse 200+ bladder diagram clip art stock illustrations and vector graphics available royalty-free, or start a new search to explore more great stock images and vector art.

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...